Maxim analyst Naz Rahman downgraded scPharmaceuticals (SCPH) to Hold from Buy after the company agreed to be acquired by MannKind (MNKD) for $5.35 per share in cash at closing plus one non-tradable contingent value right per share to receive certain milestone payments of up to an aggregate of $1.00 per CVR in cash, for total consideration of up to $6.35 per share. The firm does not expect additional bidders, noting the deal is a “definitive agreement”.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCPH:
- MannKind price target raised to $8 from $7 at RBC Capital
- scPharmaceuticals downgraded to Hold from Buy at Craig-Hallum
- H.C. Wainwright positive on MannKind deal for scPharmaceuticals
- H.C. Wainwrights positive on MannKind deal for scPharmaceuticals
- scPharmaceuticals downgraded to Hold from Buy at Maxim